Cholesterol-Lowering Activity of Naringenin via Inhibition of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase and Acyl Coenzyme A:Cholesterol Acyltransferase in Rats

  title={Cholesterol-Lowering Activity of Naringenin via Inhibition of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase and Acyl Coenzyme A:Cholesterol Acyltransferase in Rats},
  author={S.-H. Lee and Y.B. Park and Ki Hwan Bae and Song Hae Bok and Y.K. Kwon and E.S. Lee and M.-S. Choi},
  journal={Annals of Nutrition and Metabolism},
  pages={173 - 180}
The effects of dietary supplementation of a citrus bioflavonoid, naringenin, on the cholesterol metabolism were studied. For 42 days male rats were fed a 1% (wt/wt) high-cholesterol diet with or without a naringenin supplementation (0.1%, wt/wt) to study its effect on plasma lipid levels, hepatic lipid contents, activities of hepatic acyl coenzyme A:cholesterol O-acyltransferase (ACAT) and 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, and the excretion of fecal neutral sterols… 

Figures and Tables from this paper

Hypocholesterolemic and antioxidative effects of naringenin and its two metabolites in high-cholesterol fed rats.
Effect of Naringin Supplementation on Cholesterol Metabolism and Antioxidant Status in Rats Fed High Cholesterol with Different Levels of Vitamin E
Naringin supplementation significantly lowered the concentrations of plasma cholesterol and triglyceride compared to the naringin-free group in low vitamin E-fed rats, indicating that naring in lowers the plasma lipid concentrations when the dietary vitamin E level is low.
Anti-atherogenic effect of citrus flavonoids, naringin and naringenin, associated with hepatic ACAT and aortic VCAM-1 and MCP-1 in high cholesterol-fed rabbits.
The results suggest that the anti-atherogenic effect of the citrus flavonoids, naringin and naringenin, is involved with a decreased hepatic ACAT activity and with the downregulation of VCAM-1 and MCP-1 gene expression.
Dietary naringenin increases hepatic peroxisome proliferators–activated receptor α protein expression and decreases plasma triglyceride and adiposity in rats
The results indicate that the activation of PPARα transcription factor and upregulation of its fatty acid oxidation target genes by dietary naringenin may contribute to the hypolipidemic and anti-adiposity effects in vivo.
Activity and mRNA Levels of Enzymes Involved in Hepatic Fatty Acid Synthesis in Rats Fed Naringenin.
Naringenin levels in serum and liver dose-dependently increased, and hepatic concentrations reached levels that can affect various signaling pathways, and naringen in-between levels at a dietary level of 2.5 g/kg significantly decreased the activities and the mRNA levels of various lipogenic enzymes and sterol regulatory element binding protein-1c mRNA level.
In vivo metabolic effects of naringenin in the ethanol consuming rat and the effect of naringenin on adipocytes in vitro.
Results obtained in these studies demonstrate that naringenin exerts a very weak influence on carbohydrate and lipid metabolism of normal and ethanol-consuming rats and on metabolism of isolated rat adipocytes.
The present study is aimed to identify the efficacy of naringenin by uncovering its underlying mechanism of action against alcohol-induced liver disease for effective therapy, and if the biochemical and histological findings are positive, it could be subjected to human trials in the future.


Effects of ML-236B on cholesterol metabolism in mice and rats: lack of hypocholesterolemic activity in normal animals.
The results indicate that, when administered for a longer period, the drug showed no hypocholesterolemic activity in these species under either normo- or hypercholesterolems, except for rats treated with the detergent Triton WR-1339.
Rat liver acyl-coenzyme A:cholesterol acyltransferase: its regulation in vivo and some of its properties in vitro.
The hypothesis that this enzyme plays an important role in maintenance of hepatic cholesterol homeostasis is supported, as ACAT activity showed a positive correlation with changes in microsomal free and esterified cholesterol contents.
RG 12561 (dalvastatin): a novel synthetic inhibitor of HMG-CoA reductase and cholesterol-lowering agent.
In WHHL rabbits and cholestyramine-fed hamsters, RG 12561 and lovastatin reduced serum cholesterol by 17 and 16%, respectively, and these results demonstrate thatRG 12561 is a potent cholesterol-lowering agent.
Acyl-CoA:cholesterol acyltransferase in human small intestine: its activity and some properties of the enzymic reaction.
The high activity of intestinal ACAT in man renders it possible that this enzyme plays a role in cholesterol absorption.
In vivo evidence that the lipid-regulating activity of the ACAT inhibitor CI-976 in rats is due to inhibition of both intestinal and liver ACAT.
The hypothesis that orally administered CI-976 inhibits both intestinal and hepatic ACAT, and that both of these enzymes may be determinants of plasma lipid concentrations in the rat, is strongly supported.